Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | GRK2 | P25098 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16161589 | 0.99 | ROCK2 (0.44) | ROCK2ROCK1PDGFRBPDGFRARPS6KB1 | |
| SCHEMBL782068 | 0.89 | ROCK2 (0.48) | ROCK2ROCK1PDGFRBPDGFRARPS6KB1 | |
| SCHEMBL780323 | 0.89 | AKT1 (0.45) | ROCK2ROCK1PDGFRBPDGFRAKDM4E | |
| SCHEMBL782581 | 0.89 | PDGFRB (0.46) | ROCK2PDGFRBPDGFRAKDM4EALDH1A1 | |
| SCHEMBL780356 | 0.88 | PDGFRB (0.56) | ROCK2ROCK1PDGFRBPDGFRAKDM4E | |
| SCHEMBL782152 | 0.88 | ROCK2 (0.55) | ROCK2ROCK1PDGFRBPDGFRARPS6KB1 | |
| SCHEMBL782108 | 0.88 | NPBWR1 (0.46) | ROCK2PDGFRBPDGFRAPIK3CA | |
| SCHEMBL781792 | 0.87 | MKNK2 (0.46) | ROCK2ROCK1PDGFRBPDGFRARPS6KB1 | |
| Hydrochloric Acid SCHEMBL16161764 | 0.87 | ROCK2 (0.54) | ROCK2ROCK1PDGFRBPDGFRARPS6KB1 | |
| SCHEMBL782184 | 0.87 | CLK4 (0.50) | ROCK2ROCK1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3259265-B1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LTD (GB) | 2020-04-01 | — | — | EP | claimed |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | SENTINEL ONCOLOGY LIMITED (GB) | 2018-12-04 | — | — | US | claimed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | claimed |
| EP-3259265-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | Sentinel Oncology Limited (GB) | 2017-12-27 | — | — | EP | claimed |
| WO-2016131776-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2016-08-25 | — | — | WO | claimed |
| EP-2435423-B1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE | SENTINEL ONCOLOGY LTD (GB) | 2014-10-15 | — | — | EP | claimed |
| US-8716473-B2 | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | claimed |
| CN-102459234-A | Substituted benzotriazines and quinoxalines as P70S6 kinase inhibitors | SENTINEL ONCOLOGY LTD | 2012-05-16 | — | — | CN | claimed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | claimed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | claimed |
| EP-3259265-B1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LTD (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | SENTINEL ONCOLOGY LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136755-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | SENTINEL ONCOLOGY LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022735-A1 | MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER | RPS6KA1, RPS6KA3, MTOR | ROCK2 374/4885ROCK1 175/4885PDGFRB 1994/4885 |
| US-20120071478-A1 | SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE | CDK1, CDK2, CDK6 | ROCK2 733/4885ROCK1 699/4885PDGFRB 1860/4885 |
| US-10144726-B2 | Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer | RPS6KA1, RPS6KA3, MTOR | ROCK2 374/4885ROCK1 175/4885PDGFRB 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.